Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dimed Distribuidora de MedicamentosBSP:PNVL3 +2.59%88 5-Year Yield-on-Cost % is 23.63 as of Jul. 31, 2026, which is 156% above its 10-year median of 9.23. GuruFocus rates BSP:PNVL3 with a GF Score™ of 88/100 and a GF Value™ of R$13.80 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 512 Drug Manufacturers companies, Dimed Distribuidora de Medicamentos ranks better than 95.9% on this metric.
The historical rank and industry rank for Dimed Distribuidora de Medicamentos's 5-Year Yield-on-Cost % or its related term are showing as below:
BSP:PNVL3'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.73 Med: 9.23 Max: 40.79
Current: 23.63
During the past 13 years, Dimed Distribuidora de Medicamentos's highest Yield on Cost was 40.79. The lowest was 0.73. And the median was 9.23.
BSP:PNVL3's 5-Year Yield-on-Cost % is ranked better than 95.9% of 512
companies
in the Drug Manufacturers industry
Industry Median: 2.32
vs BSP:PNVL3: 23.63
Dimed Distribuidora de Medicamentos (BSP:PNVL3) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Dimed Distribuidora de Medicamentos 5-Year Yield-on-Cost % Related Terms
BSP:PNVL3 vs LLY, JNJ, ABBV: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - General subindustry, Dimed Distribuidora de Medicamentos's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dimed Distribuidora de Medicamentos 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dimed Distribuidora de Medicamentos's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Dimed Distribuidora de Medicamentos's 5-Year Yield-on-Cost % falls into.
Dimed Distribuidora de Medicamentos 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Dimed Distribuidora de Medicamentos (BSP:PNVL3) has a 5-Year Yield-on-Cost % of 23.63 as of Jul. 31, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Dimed Distribuidora de Medicamentos and its competitors. This is 156% above median its historical median of 9.23. Over the past decade, Dimed Distribuidora de Medicamentos' 5-Year Yield-on-Cost % has ranged from 0.73 to 40.79. According to the industry distribution chart, Dimed Distribuidora de Medicamentos ranks #21 out of 512 companies in the Drug Manufacturers industry, placing it in the top 4.1%.
Is Dimed Distribuidora de Medicamentos' 5-Year Yield-on-Cost % too high?
Dimed Distribuidora de Medicamentos' current 5-Year Yield-on-Cost % of 23.63 is 156% above median its 10-year median of 9.23. Over the past 10 years, this metric has ranged from a low of 0.73 to a high of 40.79. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.32. Dimed Distribuidora de Medicamentos' value of 23.63 is 918.5% above this industry median. Based on the distribution chart, Dimed Distribuidora de Medicamentos ranks #21 out of 512 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Dimed Distribuidora de Medicamentos has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dimed Distribuidora de Medicamentos' 5-Year Yield-on-Cost % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Dimed Distribuidora de Medicamentos ranks #21 out of 512 companies for 5-Year Yield-on-Cost %. This places Dimed Distribuidora de Medicamentos in the top 4% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.32. Dimed Distribuidora de Medicamentos' value of 23.63 is 918.5% above this benchmark. Historically, Dimed Distribuidora de Medicamentos' own 5-Year Yield-on-Cost % has ranged from 0.73 to 40.79 over the past decade. While the company's 10-year median is 9.23 vs. the industry median of 2.32, Dimed Distribuidora de Medicamentos has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.32, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dimed Distribuidora de Medicamentos's current 5-Year Yield-on-Cost % of 23.63 is 918.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Dimed Distribuidora de Medicamentos and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dimed Distribuidora de Medicamentos's current 5-Year Yield-on-Cost % is 23.63, which is 156% above median its own 10-year median of 9.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dimed Distribuidora de Medicamentos stock overvalued right now?
Based on GuruFocus' analysis, Dimed Distribuidora de Medicamentos (BSP:PNVL3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$13.80, compared to a current price of R$11.87 — trading 14% below its estimated fair value. The current 5-Year Yield-on-Cost % is 23.63, which is 156% above median its 10-year median of 9.23 and 918.5% above the Drug Manufacturers industry median of 2.32. Dimed Distribuidora de Medicamentos' overall GF Score™ is 88/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Dimed Distribuidora de Medicamentos (BSP:PNVL3), the current 5-Year Yield-on-Cost % is 23.63 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dimed Distribuidora de Medicamentos (BSP:PNVL3) Overvalued in 2026?
Based on GuruFocus' analysis, Dimed Distribuidora de Medicamentos stock appears to be undervalued.
The current stock price of R$11.87 is trading 14% below its estimated GF Value™ of R$13.80.
GuruFocus considers Dimed Distribuidora de Medicamentos to be Modestly Undervalued.
Key valuation signals for BSP:PNVL3:
5-Year Yield-on-Cost %: 23.63 (156% above median its 10-year median of 9.23)
GF Value™: R$13.80 vs. price of R$11.87 (14% below fair value)
Industry Position: 918.5% above the Drug Manufacturers median (#21 of 512)
No single metric tells the full story. See the BSP:PNVL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dimed SA Distribuidora de Medicamentos is engaged in the sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics. It has single reportable segment that is, The Retail segment. The Retail segment has 556 stores that sell more than 15,000 items among drugs and personal care and beauty products. In addition to adding divisions of cosmetics, drugs and food, Lifar is responsible for the production of brands in Brazil, as well as products of its own brand Panvel.
88GF Score
Get the complete analysis for BSP:PNVL3
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:PNVL3 has been successfully added to your 
